6 Results for "

ZL101

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "ZL101" in MCE Product Catalog:

5
5 Cited Publications
Cat. No.: HY-101780
CAS No.: 1236199-60-2
Purity:  99.64%
Synonyms: EDO-S101; NL-101
Target:  

HDAC

Research Areas:  

Cancer

Tinostamustine (EDO-S101) is a pan HDAC inhibitor; inhibits HDAC6, HDAC1, HDAC2 and HDAC3 with IC50 values of 6 nM, 9 nM, 9 nM and 25 nM, respectively .
loading...
    loading...
Cat. No.: HY-P991011
CAS No.: 2923556-87-8
Synonyms: AL101; GSK-4527226

Target:  

Inhibitory Antibodies

Research Areas:  

Inflammation/Immunology

HY-P991011 is an SORT1-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
loading...
    loading...
Cat. No.: HY-134193
CAS No.: 396721-89-4
Target:  

Cryptochrome

Research Areas:  

Metabolic Disease

KL101, a selective cryptochrome 1 (CRY1) stabilizer, is a circadian clock modulator. KL101 can stabilize the CRY1 protein and regulate its interaction with the core feedback loop of the biological clock, thereby modulating the circadian rhythm cycle of mammals .
loading...
    loading...
Cat. No.: HY-P991339

Research Areas:  

Cancer

ZL-1101 is a human monoclonal antibody (mAb) targeting TNFRSF4/OX40/CD134.
loading...
    loading...
Cat. No.: HY-101780A
CAS No.: 1793059-58-1
Synonyms: EDO-S101 hydrochloride; NL-101 hydrochloride
Target:  

HDAC

Research Areas:  

Cancer

Tinostamustine hydrochloride (EDO-S101 hydrochloride) is a compound with anti-multiple myeloma activity and the ability to promote CD38 expression. Tinostamustine hydrochloride enhances the sensitivity of tumor cells to the anti-CD38 monoclonal antibody daratumumab by increasing the acetylation level of histone H3. Tinostamustine hydrochloride can increase the expression of MICA and MICB, thereby activating NK cells. Tinostamustine hydrochloride can significantly delay tumor growth and improve the survival rate of mice .
loading...
    loading...
Cat. No.: HY-P991927

Target:  

CD47

Research Areas:  

Cancer

ZL-1201 is a recombinant humanized monoclonal anti-CD47 IgG4 antibody. ZL-1201 disrupt the CD47-SIRPα interaction. ZL-1201 modulates the tumor microenvironment. ZL-1201 promotes tumor-associated macrophage phagocytic activity. ZL-1201 substantially enhances phagocytosis by M2 macrophages, but not by M1 macrophages. ZL-1201 in combination with both mAb and chemotherapy achieves the maximal antitumor effects in a variety of solid tumor models. ZL-1201 can be used in the study of lymphoma, breast cancer, ovarian cancer, head and neck squamous cell carcinoma, and gastric cancer .
loading...
    loading...